Tonix Pharmaceuticals develops, discovers, commercializes, and licenses therapeutics to treat human disease. Its portfolio focuses on CNS disorders, rare diseases, immunology, and infectious diseases. The company prioritizes submitting an NDA for TNX-102 SL for fibromyalgia management and treatment of fibromyalgia-type Long COVID. Other product candidates include TNX-1300 for cocaine intoxication, TNX-2900 for Prader-Willi syndrome, and TNX-1500 for organ transplant rejection and autoimmune diseases. The company also has a pipeline of vaccines, including TNX-801, which serves as a platform for other infectious diseases. Additionally, Tonix is developing orally available CD45 antagonists, TNX-3900 and TNX-4200, in preclinical development.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 1.2 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 1.7 |